Cyclosporine: complete guide

Cyclosporine is a cyclic peptide immunosuppressant first approved by FDA as Sandimmune in 1983. This guide covers its structure, mechanism, labeled uses, trials and warnings.

Complete guide6 min read

Key takeaway

FDA first approved cyclosporine as Sandimmune on November 14, 1983. Its 11-amino-acid ring has a molecular weight of 1,202.6 g/mol. In a 1983 randomized kidney transplant trial, predicted one-year graft survival was 80.4% with cyclosporine and 64.0% with standard therapy.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Sandimmune on November 14, 1983.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited2 in this article · 2 across 1 article on Cyclosporine
Related productsBPC-157, TB-500 and thymic peptides

Cyclosporine is a ring-shaped peptide of 11 amino acids, made by a fungus, that holds back the immune system. This guide covers its structure, how it works, its FDA-labeled uses, the trials behind it and its label warnings. Sources were checked on November 17, 2026.

Quick answer: Cyclosporine is a prescription immunosuppressant. The Sandimmune and Neoral labels cover prevention of organ rejection in kidney, liver and heart transplants. Neoral also covers severe rheumatoid arthritis and severe plaque psoriasis. Restasis covers reduced tear production linked to dry eye inflammation. The transplant labels carry a boxed warning about infection and cancer risk.

Vitrapep does not sell cyclosporine; this page is a reference summary of published research and regulatory information.

What is cyclosporine?

The Sandimmune label describes cyclosporine as “a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids.” The label adds that it is “produced as a metabolite by the fungus species Beauveria nivea” (Sandimmune label, 2026).

It counts as a peptide because its backbone is a chain of amino acids joined by peptide bonds, closed into a ring. ChEBI text, quoted in PubChem, calls cyclosporin A “a cyclic nonribosomal peptide of eleven amino acids.” Nonribosomal means the fungus builds it with dedicated enzymes, not with the ribosome that makes ordinary proteins. PubChem lists the formula as C62H111N11O12 and the molecular weight as 1,202.6 g/mol (PubChem CID 5284373). See our peptide primer and peptide types.

Drugs@FDA lists the original approval of Sandimmune (NDA 050573) on November 14, 1983, to Novartis (Drugs@FDA). Neoral (NDA 050715) followed on July 14, 1995. Restasis (NDA 050790), now held by AbbVie, was approved on December 23, 2002.

Table 1

Cyclosporine: key facts

Fact Detail
Structure type Cyclic nonribosomal peptide of 11 amino acids, made by the fungus Beauveria nivea
Class Calcineurin-inhibiting immunosuppressant
Molecular formula C62H111N11O12
Molecular weight 1,202.6 g/mol
First FDA approval November 14, 1983 (Sandimmune, NDA 050573)
Brand names (US) Sandimmune, Neoral, Restasis; generic labels from many makers

How does cyclosporine work?

The Neoral label credits “specific and reversible inhibition of immunocompetent lymphocytes” in the G0 and G1 phases of the cell cycle (Neoral label, 2023). In plain terms, it stops immune cells from moving into an active, dividing state.

The molecular target was found in laboratory work. In 1991, Liu and colleagues showed in vitro that cyclosporine first binds a cell protein called cyclophilin. The cyclophilin and cyclosporine pair then binds and blocks calcineurin, an enzyme switched on by calcium and calmodulin. They concluded that calcineurin “is involved in a common step associated with T cell receptor and IgE receptor signaling pathways” (Liu et al., 1991). With calcineurin blocked, T cells respond weakly to the signals that would set off rejection.

The Restasis label is more cautious. It says cyclosporine in that product “is thought to act as a partial immunomodulator” and that “the exact mechanism of action is not known.”

What is cyclosporine approved for?

The labels list these indications:

  • Sandimmune (1983): in combination with adrenal corticosteroids, “prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants,” and “treatment of chronic rejection in patients previously treated with other immunosuppressive agents.”
  • Neoral (1995), transplant: “the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants.”
  • Neoral, rheumatoid arthritis: severe active rheumatoid arthritis “where the disease has not adequately responded to methotrexate.” It can be combined with methotrexate.
  • Neoral, psoriasis: adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed at least one systemic therapy, or who cannot use other systemic therapies.
  • Restasis (2002): “to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.”

Keratoconjunctivitis sicca is the medical name for one form of dry eye disease (Restasis label, 2024).

What did the key trials show?

Kidney transplants. The Canadian Multicentre Transplant Study Group ran a randomized human trial in 209 recipients of kidneys from deceased donors. Patients received cyclosporine with prednisone, or standard therapy with azathioprine and prednisone. Predicted one-year graft survival was 80.4% with cyclosporine and 64.0% with standard therapy. Predicted one-year patient survival was 96.6% and 86.4%. The authors concluded that cyclosporine was preferable to azathioprine for preventing rejection (Canadian Multicentre Transplant Study Group, 1983). The trial predates ClinicalTrials.gov, so it has no NCT number.

Dry eye. The Restasis label describes four multicenter, randomized, well-controlled human studies in about 1,200 patients with moderate to severe keratoconjunctivitis sicca. The end point was a 10 mm increase in Schirmer wetting, a paper-strip test of tear production. At six months, this was seen in about 15% of Restasis patients and about 5% of vehicle patients (Restasis label, 2024).

What side effects does the label list?

The Neoral and Sandimmune labels carry a boxed warning. Both say only physicians experienced in immunosuppressive therapy should prescribe the drug. The Neoral warning states that it “may increase the susceptibility to infection and the development of neoplasia.” It names lymphoma and other cancers as possible results of stronger immunosuppression in transplant patients.

For psoriasis, the Neoral warning adds a higher risk of skin cancers in patients previously treated with PUVA light therapy and some other therapies. It also warns that “renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine.” The Sandimmune warning adds that inappropriate switching between Sandimmune and Neoral can raise or lower cyclosporine exposure.

The Neoral label states: “The principal adverse reactions of cyclosporine therapy are renal dysfunction, tremor, hirsutism, hypertension, and gum hyperplasia.” Hirsutism is excess hair growth. Historical Sandimmune data from a randomized kidney trial (227 patients) show kidney dysfunction in 32%. Hypertension was 26%, hirsutism 21% and tremor 12%. The Restasis label lists eye burning (17%) as its most common adverse reaction.

What is cyclosporine’s regulatory status, and how is it used in research?

Cyclosporine is a prescription drug in the United States. A DailyMed search returns 45 cyclosporine labels, including generics from makers such as Apotex, Teva, Mylan and Lupin (DailyMed). Novartis markets Sandimmune and Neoral, and Allergan is the labeler for Restasis.

In the laboratory, cyclosporine has served as a probe of immune signaling. The 1991 in vitro study by Liu and colleagues used it to identify calcineurin as a shared signaling step. The same study showed that FK506 (tacrolimus) blocks the same enzyme through a different binding protein, FKBP.

Frequently asked questions about cyclosporine

Is cyclosporine a peptide?

Yes. It is a cyclic peptide of 11 amino acids. A fungus makes it with enzymes rather than ribosomes, so it is called nonribosomal.

When was cyclosporine first approved?

Drugs@FDA lists the original approval of Sandimmune on November 14, 1983.

What is the difference between Sandimmune and Neoral?

Both contain cyclosporine, but they are different products. Neoral was approved in 1995 and adds rheumatoid arthritis and psoriasis to its label. The Sandimmune boxed warning says inappropriate switching between them can change cyclosporine exposure.

Does cyclosporine have a boxed warning?

Yes, on the Sandimmune and Neoral labels. It covers infection risk, lymphoma and other cancers, and, for Neoral in psoriasis, kidney damage and skin cancer.

How does cyclosporine relate to calcineurin?

Laboratory work showed that cyclosporine binds cyclophilin, and the pair blocks calcineurin. This is why cyclosporine is grouped with tacrolimus as a calcineurin inhibitor.

What to know now

  • Structure: cyclic nonribosomal peptide of 11 amino acids; 1,202.6 g/mol.
  • Approval: Sandimmune, November 14, 1983; Neoral, 1995; Restasis, 2002; prescription only.
  • Mechanism: with cyclophilin, blocks calcineurin and holds T cells back.
  • Evidence: 80.4% vs 64.0% predicted one-year kidney graft survival in the 1983 Canadian trial.
  • Label: transplant rejection, severe rheumatoid arthritis, severe psoriasis, and dry eye (Restasis).
  • Safety: boxed warning on infection and cancer risk; kidney dysfunction and hypertension are common.

What we’re watching

Further revisions to the Sandimmune label on DailyMed (last revised March 2026) and the Neoral label. Related guides: zilucoplan, pegcetacoplan and daptomycin.

More for immune system

All 24 compounds for immune system

Sources: Novartis Pharmaceuticals Corporation 2026, SANDIMMUNE (cyclosporine) prescribing information; Novartis Pharmaceuticals Corporation 2023, NEORAL (cyclosporine) prescribing information; Allergan 2024, RESTASIS (cyclosporine) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 050573 (SANDIMMUNE) . Retrieved November 17, Drugs@FDA: NDA 050573 (SANDIMMUNE); U.S. Food and Drug Administration. Drugs@FDA: NDA 050715 (NEORAL) . Retrieved November 17, Drugs@FDA: NDA 050715 (NEORAL); U.S. Food and Drug Administration. Drugs@FDA: NDA 050790 (RESTASIS) . Retrieved November 17, Drugs@FDA: NDA 050790 (RESTASIS); National Center for Biotechnology Information 2026, PubChem compound summary for CID 5284373, cyclosporine; Canadian Multicentre Transplant Study Group 1983, The New England Journal of Medicine, 309; Liu 1991, Cell, 66; U.S. National Library of Medicine 2026, DailyMed search results: cyclosporine. All 10 citations

Back to the research library

References

  1. Novartis Pharmaceuticals Corporation. (2026). SANDIMMUNE (cyclosporine) prescribing information (revised 3/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e5926a7-1de0-4b54-a5c0-286b6200ff82
  2. Novartis Pharmaceuticals Corporation. (2023). NEORAL (cyclosporine) prescribing information (revised 9/2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3
  3. Allergan, Inc. (2024). RESTASIS (cyclosporine) prescribing information (revised 9/2024). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e24af2b-bc1c-4849-94f2-6df950cdca89
  4. U.S. Food and Drug Administration. Drugs@FDA: NDA 050573 (SANDIMMUNE). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050573
  5. U.S. Food and Drug Administration. Drugs@FDA: NDA 050715 (NEORAL). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050715
  6. U.S. Food and Drug Administration. Drugs@FDA: NDA 050790 (RESTASIS). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050790
  7. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 5284373, cyclosporine. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/5284373
  8. Canadian Multicentre Transplant Study Group. (1983). A randomized clinical trial of cyclosporine in cadaveric renal transplantation. The New England Journal of Medicine, 309(14), 809–815. https://doi.org/10.1056/NEJM198310063091401
  9. Liu, J., et al. (1991). Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 66(4), 807–815. https://doi.org/10.1016/0092-8674(91)90124-h
  10. U.S. National Library of Medicine. (2026). DailyMed search results: cyclosporine (45 labels). Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=cyclosporine